Kjeldsen, Julie Westerlin http://orcid.org/0000-0001-6201-1758
Lorentzen, Cathrine Lund
Martinenaite, Evelina
Ellebaek, Eva http://orcid.org/0000-0001-6748-9232
Donia, Marco http://orcid.org/0000-0003-4966-9752
Holmstroem, Rikke Boedker http://orcid.org/0000-0002-5476-9937
Klausen, Tobias Wirenfeldt
Madsen, Cecilie Oelvang
Ahmed, Shamaila Munir
Weis-Banke, Stine Emilie http://orcid.org/0000-0002-6037-494X
Holmström, Morten Orebo
Hendel, Helle Westergren
Ehrnrooth, Eva
Zocca, Mai-Britt
Pedersen, Ayako Wakatsuki
Andersen, Mads Hald
Svane, Inge Marie http://orcid.org/0000-0002-9451-6037
Article History
Received: 19 February 2021
Accepted: 20 September 2021
First Online: 9 December 2021
Change Date: 8 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-022-01771-w
Competing interests
: M.H.A. is named as an inventor on various patent applications relating to therapeutic uses of IDO and PD-L1 peptides. These patent applications are assigned to the company IO Biotech, which is developing immune-modulating cancer treatments. M.H.A. is a founder, shareholder and advisor for IO Biotech. I.M.S. is a cofounder, shareholder and advisor for IO Biotech. I.M.S. has an advisory board relationship with or lectured for Roche, Novartis, MSD, Celgene, Incyte, TILT Bio, Pfizer and BMS AstraZeneca and has received limited grants for translational research from BMS, Roche and Novartis. M.-B.Z. is the CEO, founder and shareholder at IO Biotech. E.M., A.W.P. and E. Ehrnrooth are employees at IO Biotech. E. Ellebaek has received honoraria from BMS, Pierre Fabre, Roche and Kyowa Kirin and travel support from MSD. M.D. has received honoraria from Genzyme, MSD, BMS, Roche and Novartis and travel support from Novartis, MSD, BMS, Roche and Pfizer. The remaining authors declare that they have no conflict of interest.